Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$PCRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.12 up 209.09% YoY • Reported revenue of $192.4M up 6.24% YoY • Pacira BioSciences updated full-year 2026 guidance to total revenue of $735 million to $760 million, non-GAAP SG&A expense of $310 million to $330 million, and stock-based compensation of $54 million to $59 million.

Price since post

Full Details

Advertisement|Remove ads.